← All trials
NCT03194555
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 25, 2017
- Primary completion
- Jul 26, 2018
- Completion date
- Jul 28, 2018
- First posted
- Jun 21, 2017
- Last posted
- Apr 14, 2021
- Enrollment
- 12
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Allodynic Therapeutics, LLCLead sponsor
- Allodynic Therapeutics, LLCOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.